Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 11 of 11 results for ivacaftor

  1. Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

    Evidence-based recommendations on lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del mutation.

    Technology appraisal guidance
    Published
    27 July 2016
    View recommendations

    Sections for TA398

  2. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]

    In development [GID-TA11187] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 TS ID 10767

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Data collection agreement

    treating cystic fibrosis patients with: Ivacaftor, tezacaftor and elexacaftor (Kaftrio®) in combination with ivacaftor for...

  5. Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over TS ID 11847

    Awaiting development [GID-TA11372] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

    Discontinued [GID-TA10277]

    Technology appraisal guidance
    Discontinued

  7. Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

    Discontinued [GID-TA10566]

    Technology appraisal guidance
    Discontinued

  8. Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

    Discontinued [GID-TA10390]

    Technology appraisal guidance
    Discontinued

  9. Ivacaftor for treating cystic fibrosis with mutations in the CFTR gene in babies and children aged 1 to 3 months or weighing 3 kg to 24 kg TS ID 11894

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Cystic fibrosis: diagnosis and management (NG78)

    This guideline covers diagnosing and managing cystic fibrosis. It specifies how to monitor the condition and manage the symptoms to improve quality of life. There are also detailed recommendations on treating the most common infections in people with cystic fibrosis.

    NICE guideline
    Published
    25 October 2017
    View recommendations

    Sections for NG78

  11. NICE publishes new COVID-19 guidelines on cystic fibrosis, chronic obstructive pulmonary disease (COPD) and dermatological conditions treated with drugs affecting the immune response

    NICE has today (9 April 2020) published 3 new rapid guidelines on the care of patients with suspected and confirmed COVID-19, and in patients without COVID-19. The guidelines have been designed to maximise the safety of patients whilst enabling services to make the best use of NHS resources.

    News
    Published
    9 April 2020